Seeking Alpha

The FDA extends its review date for the MS drug Tysabri - produced by Biogen Idec (BIIB) and...

The FDA extends its review date for the MS drug Tysabri - produced by Biogen Idec (BIIB) and Elan (ELN) - indicating it needs the extension to review changes in the risk evaluation and mitigation strategies for the drug. Premarket: BIIB -6%, ELN inactive.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs